{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T09:24:21Z","timestamp":1781774661712,"version":"3.54.5"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00c3\u00adfico e Tecnol\u00c3\u00b3gico","doi-asserted-by":"publisher","award":["573993\/2008-4"],"award-info":[{"award-number":["573993\/2008-4"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007381","name":"Instituto Nacional de Gen\u00c3\u00a9tica M\u00c3\u00a9dica Populacional","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007381","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00c3\u00a7\u00c3\u00a3o de Aperfei\u00c3\u00a7oamento de Pessoal de N\u00c3\u00advel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Tropica"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.actatropica.2018.02.026","type":"journal-article","created":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T11:00:24Z","timestamp":1519383624000},"page":"134-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Erythema Nodosum Leprosum: Update and challenges on the treatment of a neglected condition"],"prefix":"10.1016","volume":"183","author":[{"given":"Perp\u00e9tua do Socorro Silva","family":"Costa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Rosa","family":"Fraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thayne Woycinck","family":"Kowalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7886-3952","authenticated-orcid":false,"given":"Egon Luiz Rodrigues","family":"Daxbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2428-0460","authenticated-orcid":false,"given":"Lav\u00ednia","family":"Schuler-Faccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda Sales Luiz","family":"Vianna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.actatropica.2018.02.026_bib0005","doi-asserted-by":"crossref","first-page":"290","DOI":"10.47276\/lr.78.3.290","article-title":"Azathioprine in controlling Type 2 reactions in leprosy: a case report","volume":"78","author":"Athreya","year":"2007","journal-title":"Lepr. Rev."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0010","first-page":"491","article-title":"Studies on T cell subsets and functions in leprosy","volume":"44","author":"Bach","year":"1981","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0015","doi-asserted-by":"crossref","first-page":"637","DOI":"10.4269\/ajtmh.2010.09-0586","article-title":"Reactions following completion of 1 and 2 year multidrug therapy (MDT)","volume":"83","author":"Balagon","year":"2010","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0020","doi-asserted-by":"crossref","first-page":"213","DOI":"10.47276\/lr.82.3.213","article-title":"Does clofazimine prevent erythema nodosum leprosum (ENL) in leprosy? A retrospective study, comparing the experience of multibacillary patients receiving either 12 or 24 months WHO-MDT","volume":"82","author":"Balagon","year":"2011","journal-title":"Lepr. Rev."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0025","doi-asserted-by":"crossref","first-page":"75","DOI":"10.47878\/hi.2007.v32.35197","article-title":"Hansen\u00edase multibacilar com baciloscopia dos esfrega\u00e7os negativa: a import\u00e2ncia de se avaliar todos os crit\u00e9rios antes de se definir a forma cl\u00ednica","volume":"32","author":"Barreto","year":"2007","journal-title":"Hansen Int."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0030","first-page":"173","article-title":"Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia","volume":"60","author":"Becx-Bleumink","year":"1992","journal-title":"Int. J. Lepr. Other Mycobact. Dis."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0035","unstructured":"Brasil. 2008. Minist\u00e9rio da Sa\u00fade. Secretaria de Vigil\u00e2ncia em Sa\u00fade. Departamento de Vigil\u00e2ncia Epidemiol\u00f3gica. S\u00e9rie A. Normas e Manuais T\u00e9cnicos Cadernos de preven\u00e7\u00e3o e reabilita\u00e7\u00e3o em hansen\u00edase; n. 1, Funda\u00e7\u00e3o Nacional; Bras\u00edlia."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0040","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(04)15952-7","article-title":"Leprosy","volume":"363","author":"Britton","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.actatropica.2018.02.026_bib0045","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0002-9343(99)00408-8","article-title":"Thalidomide: current and potential clinical applications","volume":"108","author":"Calabrese","year":"2000","journal-title":"Am. J. Med."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0050","first-page":"259","article-title":"Reactional states in leprosy","volume":"22","author":"Campos","year":"1954","journal-title":"Int. J. Lepr."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0055","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1365-2141.2003.03902.x","article-title":"Thalidomide in multiple myeloma: current status and future prospects","volume":"120","author":"Cavenagh","year":"2003","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0060","doi-asserted-by":"crossref","first-page":"e0003431","DOI":"10.1371\/journal.pntd.0003431","article-title":"Household costs of leprosy reactions (ENL) in rural India","volume":"9","author":"Chandler","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0065","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/jac\/dkr444","article-title":"Clofazimine: current status and future prospects","volume":"67","author":"Cholo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0070","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijmyco.2016.02.002","article-title":"Treatment of severe refractory erythema nodosum leprosum with tumor necrosis factor inhibitor Etanercept","volume":"5","author":"Chowdhry","year":"2016","journal-title":"Int. J. Mycobacteriol."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0075","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2165\/00002018-200124020-00002","article-title":"Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing","volume":"24","author":"Clark","year":"2001","journal-title":"Drug Saf."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0080","doi-asserted-by":"crossref","first-page":"211","DOI":"10.47276\/lr.87.2.211","article-title":"Experiences with thalidomide for erythema nodosum leprosum \u2013 a retrospective study","volume":"87","author":"Darlong","year":"2016","journal-title":"Lepr. Rev."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0085","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.amjmed.2004.03.040","article-title":"Adverse effects of thalidomide administration in patients with neoplastic diseases","volume":"117","author":"Dimopoulos","year":"2004","journal-title":"Am. J. Med."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0090","first-page":"554","article-title":"Leprosy. An update: definition, pathogenesis, classification, diagnosis and treatment","volume":"104","author":"Eichelmann","year":"2013","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas (English Ed.)"},{"key":"10.1016\/j.actatropica.2018.02.026_bib0095","first-page":"739","article-title":"Treatment of recurrent erythema nodosum leprosum with infliximab","volume":"355","author":"Faber","year":"2006","journal-title":"J. Infect. Dis."},{"issue":"Suppl 1","key":"10.1016\/j.actatropica.2018.02.026_bib0100","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1590\/S0074-02762012000900020","article-title":"Genetics of leprosy reactions: an overview","volume":"107","author":"Fava","year":"2012","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.actatropica.2018.02.026_bib0105","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/S0140-6736(04)16308-3","article-title":"Thalidomide","volume":"363","author":"Franks","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.actatropica.2018.02.026_bib0110","first-page":"351","article-title":"Adrenal cortical dysfunction in leprosy","volume":"37","author":"Goldgraber","year":"1969","journal-title":"Int. J. Lepr. Other Mycobact. Dis."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0115","first-page":"389","article-title":"Erythema nodosum leprosum: clinical and therapeutic up-date","volume":"77","author":"Guerra","year":"2002","journal-title":"An. Bras. Dermatol."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0120","first-page":"1","article-title":"Projeto Diretrizes Hansen\u00edase: Epis\u00f3dios Reacionais Projeto Diretrizes","author":"Hansenologia","year":"2003","journal-title":"Proj. iretrizes"},{"key":"10.1016\/j.actatropica.2018.02.026_bib0125","doi-asserted-by":"crossref","first-page":"510","DOI":"10.4103\/2229-5178.142528","article-title":"Pentoxifylline and its applications in dermatology","volume":"5","author":"Hassan","year":"2014","journal-title":"Indian Dermatol. Online J."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0130","first-page":"105","article-title":"Using methotrexate to treat patients with ENL unresponsive to steroids and clofazimine: a report on 9 patients","volume":"84","author":"Hossain","year":"2013","journal-title":"Lepr. Rev."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0135","article-title":"The management of erythema nodosum leprosum","author":"ILEP","year":"1996","journal-title":"ILEP Tech. Bull."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0140","first-page":"FD01","article-title":"Azathioprine in chronic recalcitrant erythema nodosum leprosum: a case report","volume":"11","author":"Jitendra","year":"2017","journal-title":"J. Clin. Diagn. Res."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0145","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2133.1977.tb15196.x","article-title":"Leprosy reactional states and their treatment","volume":"97","author":"Jolliffe","year":"1977","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0150","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1590\/S0365-05962008000100010","article-title":"Leprosy type 1 reactions and erythema nodosum leprosum","volume":"83","author":"Kahawita","year":"2008","journal-title":"An. Bras. Dermatol."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0155","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1489\/1544-581X(2004)72<480:MIRE>2.0.CO;2","article-title":"Methotrexate in resistant ENL","volume":"72","author":"Kar","year":"2004","journal-title":"Int. J. Lepr. Other Mycobact. Dis."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0160","first-page":"201","article-title":"Comparison of colchicine and aspirin in the treatment of type 2 lepra reaction","volume":"59","author":"Kar","year":"1988","journal-title":"Lepr. Rev."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0165","first-page":"153","article-title":"Indomethacin in the management of erythema nodosum leprosum \u2013 a double-blind controlled trial","volume":"40","author":"Karat","year":"1969","journal-title":"Lepr. Rev."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0170","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1440-0960.2009.00534.x","article-title":"Comparative efficacy of thalidomide and prednisolone in the treatment of moderate to severe erythema nodosum leprosum: a randomized study","volume":"50","author":"Kaur","year":"2009","journal-title":"Australas J. Dermatol."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0175","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4103\/0019-5154.147791","article-title":"Comparison of bacillary index on slit skin smear with bacillary index of granuloma in leprosy and its relevance to present therapeutic regimens","volume":"60","author":"Kumaran","year":"2015","journal-title":"Indian J. Dermatol."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0180","doi-asserted-by":"crossref","first-page":"e0004149","DOI":"10.1371\/journal.pntd.0004149","article-title":"Comparison of efficacy and safety of ciclosporin to prednisolone in the treatment of erythema nodosum leprosum: two randomised, double blind, controlled pilot studies in Ethiopia","volume":"10","author":"Lambert","year":"2016","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0185","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1086\/345872","article-title":"Adrenocortical hormones and interleukin patterns in paracoccidioidomycosis","volume":"187","author":"Leal","year":"2003","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0190","first-page":"253","article-title":"The management of erythema nodosum leprosum: current and future options","volume":"67","author":"Lockwood","year":"1996","journal-title":"Lepr. Rev."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0195","first-page":"28","article-title":"The histopathology and histochemistry of erythema nodosum leprosum","volume":"33","author":"Mabalay","year":"1965","journal-title":"Int. J. Lepr."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0200","doi-asserted-by":"crossref","first-page":"171","DOI":"10.47276\/lr.74.2.171","article-title":"Pulse dexamethasone, oral steroids and azathioprine in the management of erythema nodosum leprosum","volume":"74","author":"Mahajan","year":"2003","journal-title":"Lepr. Rev."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0205","first-page":"547","article-title":"Oral zinc in recurrent erythema nodosum leprosum reaction","volume":"55","author":"Mathur","year":"1983","journal-title":"Lepr. India"},{"key":"10.1016\/j.actatropica.2018.02.026_bib0210","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.biocel.2007.01.022","article-title":"The thalidomide saga","volume":"39","author":"Melchert","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0215","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1590\/S0365-05962008000400010","article-title":"Imunologia da hansen\u00edase","volume":"83","author":"Mendon\u00e7a","year":"2008","journal-title":"An. Bras. Dermatol."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0220","unstructured":"Minist\u00e9rio da Sa\u00fade, 2001. Regionaliza\u00e7\u00e3o da assist\u00eancia \u00e0 sa\u00fade: aprofundando a descentraliza\u00e7\u00e3o com eq\u00fcidade no acesso: Norma Operacional da Assist\u00eancia \u00e0 Sa\u00fade\u2014NOAS-SUS 01\/01 [WWW Document]. URL http:\/\/siops.datasus.gov.br\/Documentacao\/Noas01de2001.pdf (Accessed 8.14.17)."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0225","unstructured":"Minist\u00e9rio da Sa\u00fade, 2002. Regionaliza\u00e7\u00e3o da assist\u00eancia \u00e0 sa\u00fade: aprofundando a descentraliza\u00e7\u00e3o com eq\u00fcidade no acesso: Norma Operacional da Assist\u00eancia \u00e0 Sa\u00fade\u2014NOAS-SUS 01\/02 [WWW Document]. URL http:\/\/siops.datasus.gov.br\/Documentacao\/NOAS01de2002.pdf (Accessed 8.14.17)."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0230","unstructured":"Minist\u00e9rio da Sa\u00fade, 2010. Orienta\u00e7\u00f5es para uso: corticosteroides em hansen\u00edase http:\/\/bvsms.saude.gov.br\/bvs\/publicacoes\/orientacoes_para_corticosteroides_hanseniase.pdf."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0235","unstructured":"Minist\u00e9rio da Sa\u00fade, 2011. RDC no 11, de 22 de Mar\u00e7o de 2011 [WWW Document]. URL http:\/\/bvsms.saude.gov.br\/bvs\/saudelegis\/anvisa\/2011\/res0011_21_03_2011.html (Accessed 8.14.17)."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0240","unstructured":"Minist\u00e9rio da Sa\u00fade, 2016. Diretrizes para vigil\u00e2ncia, aten\u00e7\u00e3o e eliminacao da hansen\u00edase como problema de sa\u00fade p\u00fablica: manual t\u00e9cnico-operacionalhanseniase."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0245","unstructured":"Minist\u00e9rio da Sa\u00fade. Brazil, 2005. Guia de Vigil\u00e2ncia Epidemiol\u00f3gica [WWW Document]. URL http:\/\/bvsms.saude.gov.br\/bvs\/publicacoes\/Guia_Vig_Epid_novo2.pdf (Accessed 8.13.17)."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0250","first-page":"327","article-title":"A review of side-effects experienced by patients taking clofazimine","volume":"54","author":"Moore","year":"1983","journal-title":"Lepr. Rev."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0255","doi-asserted-by":"crossref","DOI":"10.1046\/j.1365-3083.1999.00622.x","article-title":"Cytokine mRNA expression in leprosy: a possible role for interferon-gamma and interleukin-12 in reactions (RR and ENL)","author":"Moraes","year":"1999","journal-title":"Scand. J. Immunol"},{"key":"10.1016\/j.actatropica.2018.02.026_bib0260","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1084\/jem.177.6.1675","article-title":"Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation","volume":"177","author":"Moreira","year":"1993","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0265","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.6061\/clinics\/2012(10)05","article-title":"Leprosy reactions: coinfections as a possible risk factor","volume":"67","author":"Motta","year":"2012","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.actatropica.2018.02.026_bib0270","series-title":"Leprosy","first-page":"219","article-title":"Reactions in leprosy","author":"Naafs","year":"2012"},{"key":"10.1016\/j.actatropica.2018.02.026_bib0275","doi-asserted-by":"crossref","first-page":"379","DOI":"10.47276\/lr.86.4.379","article-title":"Effectiveness of methotrexate in prednisolone and thalidomide resistant cases of Type 2 lepra reaction: report on three cases","volume":"86","author":"Nagar","year":"2015","journal-title":"Lepr. Rev."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0280","first-page":"148","article-title":"Les\u00f5es renais em hansen\u00edase","volume":"17","author":"Nakayama","year":"1995","journal-title":"J. Bras. Nefrol."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0285","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1590\/S0036-46651998000600005","article-title":"Reactional states in multibacillary Hansen disease patients during multidrug therapy","volume":"40","author":"Nery","year":"1998","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"key":"10.1016\/j.actatropica.2018.02.026_bib0290","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1590\/S0365-05962006000400010","article-title":"Contribution to diagnosis and management of reactional states: a practical approach","volume":"81","author":"Nery","year":"2006","journal-title":"Ann. Bras. Dermatol."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0295","first-page":"262","article-title":"Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells","volume":"83","author":"Neuner","year":"1994","journal-title":"Immunology"},{"key":"10.1016\/j.actatropica.2018.02.026_bib0300","first-page":"339","article-title":"Special workshop on repeated and late reactions","volume":"70","author":"Nicholls","year":"2002","journal-title":"Int. J. Lepr. Other Mycobact. Dis."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0305","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0090-1229(92)90088-6","article-title":"Serum tumor necrosis factor and interleukin 1 in leprosy and during lepra reactions","volume":"63","author":"Parida","year":"1992","journal-title":"Clin. Immunol. Immunopathol."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0310","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jaad.2005.07.059","article-title":"Azathioprine in dermatology: the past, the present, and the future","volume":"55","author":"Patel","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0315","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1590\/S0365-05962005000600010","article-title":"Thalidomide in the treatment of erythema nodosum leprosum (ENL): systematic review of clinical trials and prospects of new investigations","volume":"80","author":"Penna","year":"2005","journal-title":"An. Bras. Dermatol."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0320","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.adengl.2011.12.010","article-title":"Deep vein thrombosis in a patient with lepromatous leprosy receiving thalidomide to treat leprosy reaction","volume":"104","author":"Petiti-Martin","year":"2013","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas (English Edition)"},{"key":"10.1016\/j.actatropica.2018.02.026_bib0325","first-page":"36","article-title":"A demanda de uma unidade de refer\u00eancia estadual em hansen\u00edase no norte do brasil","volume":"10","author":"Pires","year":"2011","journal-title":"Rev. Hosp. Univ. Pedro Ernesto"},{"key":"10.1016\/j.actatropica.2018.02.026_bib0330","doi-asserted-by":"crossref","DOI":"10.4269\/ajtmh.2006.74.868","article-title":"Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad","author":"Pocaterra","year":"2006","journal-title":"India Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0335","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fimmu.2017.00233","article-title":"A systematic review of immunological studies of erythema nodosum leprosum","volume":"8","author":"Polycarpou","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0340","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.piel.2015.04.015","article-title":"Tratamiento de las leprorreacciones","volume":"30","author":"Pulido P\u00e9rez","year":"2015","journal-title":"Piel"},{"key":"10.1016\/j.actatropica.2018.02.026_bib0345","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/cid\/ciq213","article-title":"Severe refractory erythema nodosum leprosum successfully treated with the tumor necrosis factor inhibitor etanercept","volume":"52","author":"Ramien","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0350","series-title":"Rang and Dale\u2019s Pharmacology","author":"Rang","year":"2012"},{"key":"10.1016\/j.actatropica.2018.02.026_bib0355","first-page":"255","article-title":"Classification of leprosy according to immunity: a five-group system","volume":"34","author":"Ridley","year":"1966","journal-title":"Int. J. Lepr. Other Mycobact. Dis."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0360","first-page":"77","article-title":"Reactions in leprosy","volume":"40","author":"Ridley","year":"1969","journal-title":"Lepr. Rev."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0365","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijid.2016.02.018","article-title":"Leprosy classification methods: a comparative study in a referral center in Brazil","volume":"45","author":"J\u00fanior","year":"2016","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0370","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1529-8019.2007.00132.x","article-title":"Dermatologic therapeutics: thalidomide. A practical guide","volume":"20","author":"Rosenbach","year":"2007","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0375","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1590\/S0100-879X2007000200011","article-title":"Double-blind trial of the efficacy of pentoxifylline vs thalidomide for the treatment of type II reaction in leprosy","volume":"40","author":"Sales","year":"2007","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0380","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s004150050068","article-title":"Immunological monitoring of azathioprine treatment in multiple sclerosis patients","volume":"244","author":"Salmaggi","year":"1997","journal-title":"J. Neurol."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0385","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1084\/jem.173.3.699","article-title":"Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes","volume":"173","author":"Sampaio","year":"1991","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0390","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0753-3322(01)00147-0","article-title":"Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. leprae-induced TNF\u03b1 production in vitro","volume":"56","author":"Sampaio","year":"2002","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0395","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1590\/abd1806-4841.20175471","article-title":"Etanercept in erythema nodosum leprosum","volume":"92","author":"Santos","year":"2017","journal-title":"An. Bras. Dermatol."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0400","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/infdis\/168.2.408","article-title":"The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum","volume":"168","author":"Sarno","year":"1993","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0405","first-page":"318","article-title":"ENL reactions in the multibacillary cases of the AMFES cohort in central Ethiopia. Incidence and risk factors","volume":"71","author":"Saunderson","year":"2000","journal-title":"Lepr. Rev."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0410","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/bdra.20384","article-title":"New cases of thalidomide embryopathy in Brazil","volume":"79","author":"Schuler-Faccini","year":"2007","journal-title":"Birth Defects Res. Part A Clin. Mol. Teratol."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0415","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1128\/CMR.19.2.338-381.2006","article-title":"The continuing challenges of leprosy","volume":"19","author":"Scollard","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0420","first-page":"5","article-title":"Thalidomide\u2019s effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood","volume":"63","author":"Shannon","year":"1992","journal-title":"Lepr. Rev."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0425","doi-asserted-by":"crossref","first-page":"164","DOI":"10.47276\/lr.83.2.164","article-title":"Bacteriological results and leprosy reactions among MB leprosy patients treated with uniform multidrug therapy in China","volume":"83","author":"Shen","year":"2012","journal-title":"Lepr. Rev."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0430","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/cpt196563303","article-title":"Thalidomide in the treatment of lepra reactions","volume":"6","author":"Sheskin","year":"1965","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0435","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/jmg.29.10.716","article-title":"Recognition of thalidomide defects","volume":"29","author":"Smithells","year":"1992","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0440","doi-asserted-by":"crossref","first-page":"325","DOI":"10.11606\/issn.2176-7262.v30i3p325-334","article-title":"Hansen\u00edase: formas cl\u00ednicas e diagn\u00f3stico diferencial","volume":"30","author":"Souza","year":"1997","journal-title":"Medicina (Ribeir\u00e3o Preto. Online)"},{"key":"10.1016\/j.actatropica.2018.02.026_bib0445","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/S0006-291X(88)81271-3","article-title":"Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline","volume":"155","author":"Strieter","year":"1988","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0450","first-page":"10","article-title":"Leprosy reactions \u2013 complications of steroid therapy","volume":"66","author":"Sugumaran","year":"1998","journal-title":"Int. J. Lepr. Other Mycobact. Dis."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0455","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1286-4579(02)01645-3","article-title":"Thalidomide in the treatment of leprosy","volume":"4","author":"Teo","year":"2002","journal-title":"Microbes Infect."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0460","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/BF03401576","article-title":"Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis","volume":"1","author":"Tramontana","year":"1995","journal-title":"Mol. Med."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0465","doi-asserted-by":"crossref","first-page":"67","DOI":"10.47878\/hi.2007.v32.35196","article-title":"Tratamento e controle das rea\u00e7\u00f5es hans\u00eanicas","volume":"32","author":"Ura","year":"2007","journal-title":"Hansenol. Int."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0470","doi-asserted-by":"crossref","first-page":"355","DOI":"10.47276\/lr.80.4.355","article-title":"Interventions for erythema nodosum leprosum. A Cochrane review","volume":"80","author":"Van Veen","year":"2009","journal-title":"Lepr. Rev."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0475","doi-asserted-by":"crossref","first-page":"225","DOI":"10.47276\/lr.77.3.225","article-title":"Role of azathioprine in preventing recurrences in a patient of recurrent erythema nodosum leprosum","volume":"77","author":"Verma","year":"2006","journal-title":"Lepr. Rev."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0480","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/MCD.0b013e32835ffc58","article-title":"Recognition of the phenotype of thalidomide embryopathy in countries endemic for leprosy","volume":"22","author":"Vianna","year":"2013","journal-title":"Clin. Dysmorphol."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0485","doi-asserted-by":"crossref","first-page":"518","DOI":"10.4269\/ajtmh.2005.72.518","article-title":"A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum","volume":"72","author":"Villahermosa","year":"2005","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0490","doi-asserted-by":"crossref","first-page":"e2440","DOI":"10.1371\/journal.pntd.0002440","article-title":"A systematic review on the epidemiological data of erythema nodosum leprosum, a type 2 leprosy reaction","volume":"7","author":"Voorend","year":"2013","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0495","series-title":"1998 WHO Expert Committee on Leprosy Seventh Report.pdf","author":"World Health Organization","year":"1998"},{"key":"10.1016\/j.actatropica.2018.02.026_bib0500","doi-asserted-by":"crossref","first-page":"407","DOI":"10.47276\/lr.86.4.407","article-title":"Erythema nodosum leprosum international study group: 3rd ENLIST meeting report, Mumbai, 7th\u20139th april 2015","volume":"86","author":"Walker","year":"2015","journal-title":"Lepr. Rev."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0505","doi-asserted-by":"crossref","first-page":"197","DOI":"10.47276\/lr.78.3.197","article-title":"The role of thalidomide in the management of erythema nodosum leprosum","volume":"78","author":"Walker","year":"2007","journal-title":"Lepr. Rev."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0510","doi-asserted-by":"crossref","first-page":"396","DOI":"10.47276\/lr.83.4.396","article-title":"International workshop on erythema nodosum leprosum (ENL) \u2013 consensus report; the formation of ENLIST, the ENL international study group","volume":"83","author":"Walker","year":"2012","journal-title":"Lepr. Rev."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0515","doi-asserted-by":"crossref","first-page":"e2690","DOI":"10.1371\/journal.pntd.0002690","article-title":"The mortality associated with erythema nodosum leprosum in Ethiopia: a retrospective hospital-based study","volume":"8","author":"Walker","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0520","doi-asserted-by":"crossref","first-page":"e0004065","DOI":"10.1371\/journal.pntd.0004065","article-title":"ENLIST 1: an international multi-centre cross-sectional study of the clinical features of erythema nodosum leprosum","volume":"9","author":"Walker","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0525","first-page":"282","article-title":"Imbalances in T cell subpopulations in lepromatous leprosy","volume":"50","author":"Wallach","year":"1982","journal-title":"Int. J. Lepr. Other Mycobact. Dis."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0530","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(69)90592-3","article-title":"Erythema nodosum leprosum: a clinical manifestation of the arthus phenomenon","volume":"294","author":"Wemambu","year":"1969","journal-title":"Lancet"},{"key":"10.1016\/j.actatropica.2018.02.026_bib0535","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1440-0960.2002.00608.x","article-title":"Thalidomide in dermatology","volume":"43","author":"Wines","year":"2002","journal-title":"Australas. J. Dermatol."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0540","unstructured":"World Health Organization, 2002. Report on Third Meeting of the WHO Technical Advisory Group on Elimination of Leprosy [WWW Document]. URL http:\/\/www.who.int\/lep (Accessed 8.14.17)."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0545","first-page":"2006","article-title":"Global strategy for further reducing the leprosy burden and sustaining leprosy control activities","author":"World Health Organization,","year":"2006","journal-title":"Operational Guidelines"},{"key":"10.1016\/j.actatropica.2018.02.026_bib0550","unstructured":"World Health Organization, 2012. WHO Expert Committee on Leprosy: eighth report. I.World Heal. Organ. II.WHO Expert Comm. Lepr. III. Series. ISBN 978, 92\u20134."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0555","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2133.2005.06747.x","article-title":"Thalidomide: dermatological indications, mechanisms of action and side-effects","volume":"153","author":"Wu","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0560","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/j.1346-8138.2011.01484.x","article-title":"Deep venous thrombosis and pulmonary embolism secondary to co-administration of thalidomide and oral corticosteroid in a patient with leprosy","volume":"39","author":"Yamaguchi","year":"2012","journal-title":"J. Dermatol."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0565","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.4049\/jimmunol.149.4.1470","article-title":"Cytokine patterns of immunologically mediated tissue damage","volume":"149","author":"Yamamura","year":"1992","journal-title":"J. Immunol."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0570","doi-asserted-by":"crossref","DOI":"10.1183\/09031936.06.00131505","article-title":"Thalidomide reduces IL-18, IL-8 and TNF-\u03b1 release from alveolar macrophages in interstitial lung disease","author":"Ye","year":"2006","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0575","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0190-9622(91)70196-9","article-title":"Azathioprine in dermatology","volume":"25","author":"Younger","year":"1991","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0580","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1182\/blood.V98.5.1614","article-title":"Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy","volume":"98","author":"Zangari","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.actatropica.2018.02.026_bib0585","first-page":"2","article-title":"Pentoxifylline: a drug with wide spectrum applications in dermatology","volume":"14","author":"Zargari","year":"2008","journal-title":"Dermatol. Online J."},{"key":"10.1016\/j.actatropica.2018.02.026_bib0590","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/asheducation-2006.1.348","article-title":"Thrombotic complications of myeloma therapy","author":"Zonder","year":"2006","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"}],"container-title":["Acta Tropica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001706X17311166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001706X17311166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:19:49Z","timestamp":1762075189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001706X17311166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":118,"alternative-id":["S0001706X17311166"],"URL":"https:\/\/doi.org\/10.1016\/j.actatropica.2018.02.026","relation":{},"ISSN":["0001-706X"],"issn-type":[{"value":"0001-706X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Erythema Nodosum Leprosum: Update and challenges on the treatment of a neglected condition","name":"articletitle","label":"Article Title"},{"value":"Acta Tropica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actatropica.2018.02.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}